Kaneka Eurogentec

Seraing, BE
mRNA Plasmid Oligonucleotide
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
63.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (1)

Quick Facts: Kaneka Eurogentec

Signal Score
63.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Seraing, BE
Modalities
mRNA, Plasmid, Oligonucleotide
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesmRNA, Plasmid, Oligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Kaneka Corporation (4118.T)
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Kaneka Corporation
SEC FilingsParent: Kaneka Corporation
Parent company: Kaneka Corporation (4118.T)
Financial assessment: 68.0/100
Capacity 58.0
1 CGT manufacturing site: Seraing, Belgium
Modalities: mRNA, Plasmid, Oligonucleotide
Capacity assessment: 58.0/100
Sites: Seraing, Belgium
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press1 articles
1 CGT manufacturing site: Seraing, Belgium
Modalities: mRNA, Plasmid, Oligonucleotide
Capacity assessment: 58.0/100

Recent News 1 articles

regulatory 2026-03-12
Custom DNA Oligos Market to 2035 Driven by Accelerated R&D in Nucleic Acid Therapeutics - IndexBox - Market Intelligence Platform
Custom DNA Oligos Market to 2035 Driven by Accelerated R&D in Nucleic Acid Therapeutics  IndexBox - Market Intelligence Platform
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs → Plasmid CDMOs → Oligonucleotide CDMOs →